COAG
Hemab Therapeutics Holdings, Inc.$52.44
-2.15%
vs $53.59
Mkt Cap $2.4B
52w Low $23.00
90.8% of range
52w High $55.42
50d MA $39.55
200d MA $35.46
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
—
ROE
—
P/FCF
—
RSI (14)
66.90
ATR (14)
$3.88
Beta
—
50d MA
$39.55
200d MA
$35.46
Avg Volume
—
CIK (SEC)
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | BMO | -0.73 | -0.80 | -9.2% | 49.87 | +0.0% | +3.7% | +3.4% | +0.9% | +1.8% | -2.5% | — |
| May 21, 2026 | BMO | -23.25 | -23.98 | -3.2% | 26.30 | +0.0% | -1.6% | +7.5% | +2.7% | -2.1% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 | H.C. Wainwright | Initiates | Buy | $40 | $25.51 | $26.21 | +2.7% | +3.7% | +10.5% | +8.5% | -8.2% | -1.4% |
| May 26 | Evercore ISI | Initiates | Outperform | $50 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Goldman | Initiates | Buy | $36 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Jefferies | Initiates | Buy | $39 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Wedbush | Initiates | Outperform | $42 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 61,523 | $24.98 | $1.5M | 6,444,637 | +10.55% | -3.62% |
| Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,146 | $24.89 | $153K | 6,383,114 | +10.55% | -3.62% |
| May 20, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 996 | $24.94 | $25K | 6,376,968 | -1.56% | +1.79% |
| May 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 3,802 | $24.97 | $95K | 6,375,972 | -1.56% | +1.79% |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,387 | $24.90 | $159K | 6,372,170 | -1.06% | -0.64% |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 25,720 | $25.00 | $643K | 6,365,783 | +3.60% | -3.28% |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 14,149 | $24.47 | $346K | 6,340,063 | +3.60% | -3.28% |
| May 8, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 1,483 | $24.98 | $37K | 6,325,914 | +3.60% | -3.28% |
| May 7, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 1,985 | $24.95 | $50K | 6,324,431 | +3.60% | -3.28% |
| May 7, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 7,921 | $24.34 | $193K | 6,322,446 | +3.60% | -3.28% |
| May 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 53,407 | $24.83 | $1.3M | 6,314,525 | +2.92% | +10.27% |
| May 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 14,611 | $23.77 | $347K | 6,261,118 | +2.92% | +10.27% |
| May 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 10,268 | $25.00 | $257K | 6,246,507 | +2.92% | +10.27% |
| May 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 87,143 | $24.59 | $2.1M | 6,236,239 | +2.92% | +10.27% |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 133,750 | $18.00 | $2.4M | 354,938 | +2.92% | +10.27% |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 2,541,250 | $18.00 | $45.7M | 6,149,096 | +2.92% | +10.27% |
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Aug 11
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Hemab Therapeutics' sutacimig received FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, potentially accelerating development and approval timelines for this rare blood disorder treatment.
May 21
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Hemab Therapeutics (COAG) completed its IPO on May 4, 2026, with amended bylaws and restated certificate of incorporation taking effect at closing.
May 4
Institutional (13F) — Top 12
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 3,602,093 | $132M | New | Jun 2026 |
| 2 | Siren, L.l.c. | 2,086,834 | $77M | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 780,758 | $29M | New | Jun 2026 |
| 4 | Citadel Advisors Llc | 523,450 | $19M | New | Jun 2026 |
| 5 | Blackrock, Inc. | 283,833 | $10M | New | Jun 2026 |
| 6 | Aberdeen Group Plc | 52,117 | $2M | New | Jun 2026 |
| 7 | Td Asset Management Inc | 33,098 | $1M | New | Jun 2026 |
| 8 | Soros Fund Management Llc | 25,000 | $918K | New | Jun 2026 |
| 9 | Landscape Capital Management, L.l.c. | 13,183 | $484K | New | Jun 2026 |
| 10 | Vanguard Portfolio Management Llc | 8,169 | $300K | New | Jun 2026 |
| 11 | Two Sigma Investments, Lp | 5,680 | $209K | New | Jun 2026 |
| 12 | Citigroup Inc | 2,095 | $77K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Strategic Advisers Fidelity U.S. Total Stock Fund | 412,400 | $12M | May 2026 |
| 2 | Select Biotechnology Portfolio | 379,476 | $11M | May 2026 |
| 3 | Multi-Manager Small Cap Equity Strategies Fund | 75,644 | $2M | May 2026 |
| 4 | Select Health Care Portfolio | 65,000 | $2M | May 2026 |
Valuation
Market Cap
$2.45B
Enterprise Value
—
P/E (TTM)
—
Forward P/E
—
PEG Ratio
—
P/B
—
P/S
—
P/FCF
—
EV/EBITDA
—
Shares Out
—
Financials (TTM)
Revenue
—
Net Income
—
EBITDA
—
Free Cash Flow
—
Op Cash Flow
—
EPS Basic
—
EPS Diluted
—
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
—
Total Liab.
—
Total Equity
—
Cash
—
LT Debt
—
Book Value/Sh
—
Debt/Equity
—
Current Ratio
—
Quick Ratio
—
Returns & Growth
ROE
—
ROA
—
ROIC
—
Rev Growth YoY
—
EPS Growth YoY
—
Price Returns
2W
+19.1%
1M
+8.7%
3M
+97.4%
6M
+57.6%
12M
+57.6%
Technicals
52W High
$55.42
52W Low
$23.00
50d MA
$39.55
200d MA
$35.46
RSI (14)
66.90
ATR (14)
$3.88
Beta
—
Avg Volume
—
Dividends
Div Rate
—
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
· Source: financialmodelingprep.com